학술논문

Serum levels of candidate microRNA diagnostic markers differ among the stages of non-small-cell lung cancer.
Document Type
Article
Source
Oncology Letters. Nov2018, Vol. 16 Issue 5, p6643-6651. 9p.
Subject
*NON-small-cell lung carcinoma
*MICRORNA
*CANCER diagnosis
*CANCER patients
*LUNG cancer
Language
ISSN
1792-1074
Abstract
Circulating microRNAs (miRNAs) are promising markers for cancer diagnosis and prognosis. Numerous studies evaluating miRNAs as markers for non-small cell lung cancer (NSCLC) have been conducted in recent years; however, the majority of candidate markers proposed via individual studies were inconsistent and no marker miRNAs for the diagnosis of early stage NSCLC have been established. In the present study, miR-145, miR-20a, miR-21 and miR-223, which were previously reported as candidate diagnostic markers of NSCLC, were re-evaluated. The serum levels of these miRNAs were quantified in 56 patients with stage I–IV NSCLC using the TaqMan microRNA assays and separately compared the levels at each stage with those in 26 control patients. The level of miR-145 was significantly reduced in patients with NSCLC, regardless of clinical stage, and its level increased following tumor resection in patients with stage I–II disease. These results indicate that miR-145 is relevant as a diagnostic marker for stages I–IV NSCLC. Additionally, the levels of miR-20a and miR-21 demonstrated notable differences among patients at different clinical stages. These miRNAs distinguished patients in a number of, but not all, stages of NSCLC from cancer-free control patients. These results indicated that it is essential to analyze miRNA levels at each stage separately in order to evaluate marker miRNAs for NSCLC diagnosis. [ABSTRACT FROM AUTHOR]